Factor X (F10) is a vitamin K-dependent serine protease that plays dual roles in hemostasis and inflammation. Its primary function involves blood coagulation, where Factor Xa converts prothrombin to thrombin in the presence of Factor Va, calcium, and phospholipid 1. The F10 gene, located on chromosome 13 and containing 8 exons, encodes this essential coagulation factor that is synthesized mainly by the liver 1. Factor Xa also activates pro-inflammatory signaling pathways through protease-activated receptors (PARs), triggering production of inflammatory cytokines such as MCP-1/CCL2, IL6, and TNF in endothelial cells and cardiac tissues. Factor X deficiency is a rare, recessively inherited bleeding disorder affecting 1 in 1,000,000 people, representing 10% of all rare bleeding diseases 1. The clinical presentation includes severe bleeding manifestations such as hemarthroses, hematomas, and umbilical cord, gastrointestinal, and central nervous system bleeding 1. Over 105 mutations in F10 have been identified, with 78% being missense mutations 1. Treatment involves fresh-frozen plasma or prothrombin complex concentrates, though specific Factor X concentrates have been developed to minimize thrombotic complications 1.